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Nonalcoholic fatty liver is associated with obesity-related metabolic disturbances, but little is known about the metabolic
perturbations preceding fatty liver disease. We performed comprehensive metabolic proﬁling to assess how circulating
metabolites, such as lipoprotein lipids, fatty acids, amino acids, and glycolysis-related metabolites, reﬂect the presence of
and future risk for fatty liver in young adults. Sixty-eight lipids and metabolites were quantiﬁed by nuclear magnetic reso-
nance metabolomics in the population-based Young Finns Study from serum collected in 2001 (n 5 1,575), 2007 (n 5
1,509), and 2011 (n 5 2,002). Fatty liver was diagnosed by ultrasound in 2011 when participants were aged 34-49 years
(19% prevalence). Cross-sectional associations as well as 4-year and 10-year risks for fatty liver were assessed by logistic
regression. Metabolites across multiple pathways were strongly associated with the presence of fatty liver (P < 0.0007 for
60 measures in age-adjusted and sex-adjusted cross-sectional analyses). The strongest direct associations were observed for
extremely large very-low-density lipoprotein triglycerides (odds ratio [OR] 5 4.86 per 1 standard deviation, 95% conﬁ-
dence interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chain amino acids (e.g., leucine
OR 5 2.94, 2.51-3.44). Strong inverse associations were observed for high-density lipoprotein measures, e.g., high-density
lipoprotein size (OR 5 0.36, 0.30-0.42) and several fatty acids including omega-6 (OR 5 0.37, 0.32-0.42). The metabolic
associations were attenuated but remained signiﬁcant after adjusting for waist, physical activity, alcohol consumption, and
smoking (P < 0.0007). Similar aberrations in the metabolic proﬁle were observed already 10 years before fatty liver diagno-
sis. Conclusion: Circulating lipids, fatty acids, and amino acids reﬂect fatty liver independently of routine metabolic risk fac-
tors; these metabolic aberrations appear to precede the development of fatty liver in young adults. (HEPATOLOGY
2017;65:491-500).
In conjunction with the rising prevalence of obesity,nonalcoholic fatty liver disease has become a majorpublic health problem that affects every third adult
in developed countries.(1) Physical inactivity(2) and
unhealthy dietary habits(3) are the major behavioral risk
factors of fatty liver. Fatty liver is robustly associated
with well-known cardiometabolic risk factors (such as
obesity, dyslipidemia, and insulin resistance) and
increases the risk for type 2 diabetes and cardiovascular
disease.(4,5) Fatty liver, i.e., mild steatosis, can develop
into more severe liver disease, an inﬂammatory steatohe-
patitis, and irreversible ﬁbrosis or cirrhosis.(1) Although
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fatty liver is related to obesity and insulin resistance, its
molecular pathogenesis remains poorly understood, and
therapeutic options are limited.(1,6)
Fatty liver is caused by the accumulation of triglycer-
ide deposits in the liver and their tendency to form lip-
id droplets.(1) Fat accumulation has been linked to
increased nonesteriﬁed fatty acid inﬂow to the liver,
hepatic de novo lipogenesis, impaired mitochondrial fat
oxidation, and inadequate hepatic fat secretion through
very-low-density lipoproteins (VLDLs).(1,7) Because
the function of the liver is critical in multiple pathways
regulating systemic metabolism, it can be argued that
characterizing a metabolic signature of mild steatosis
may shed light on the pathogenesis of fatty liver dis-
ease. Until now, metabolomics studies on fatty liver
have been conducted in small cross-sectional case–con-
trol settings or in connection with bariatric surgery.
These studies have revealed signiﬁcant associations of
overt nonalcoholic steatosis and steatohepatitis with
levels of lipoprotein lipids, fatty acids, amino acids,
and ketone bodies.(8-12) However, there is a paucity of
long-term prospective studies with comprehensive
metabolic proﬁling of blood samples from apparently
healthy, young individuals. In order to elucidate the
metabolic disturbances associated with not only the
clinical manifestations of fatty liver but also the
changes preceding the appearance of its signs and
symptoms, we assessed cross-sectional and prospective
associations of 68 circulating lipoprotein lipids, fatty
acids, amino acids, and other metabolic measures with
fatty liver disease in a general-population cohort of
young and middle-aged men and women. We hypoth-
esized that circulating metabolites would be bio-
markers for the presence of fatty liver and tested
whether the metabolites would even be predictive for
the risk of future fatty liver disease onset.
Materials and Methods
STUDY POPULATION
The Cardiovascular Risk in Young Finns Study is a
population-based, multicenter cohort follow-up study
being conducted in ﬁve Finnish university hospitals.
The study began in 1980, when 3,596 children and
adolescents (83.1% of those invited) aged 3, 6, 9, 12,
15, and 18 years randomly chosen from the Finnish
national population register participated in the ﬁrst
clinical examinations.(13) When they reached adult-
hood, follow-up examinations were carried out in
2001, 2007, and 2011. In the 2011 survey, liver fat sta-
tus was examined with ultrasound for 2,046 partici-
pants, who were then between 34 and 49 years old.
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The analyses included in the present study include
both cross-sectional and prospective approaches. The
cross-sectional analyses of the 2011 survey data include
n 5 2,002 participants with assessment of liver fat sta-
tus and metabolic measures quantiﬁed by nuclear
magnetic resonance (NMR) metabolomics. The pro-
spective analyses focus on the metabolic measures
quantiﬁed from serum samples collected in 2001 (base-
line of the present study) as predictors of fatty liver in
2011 for n 5 1,575 participants. The metabolic associ-
ations in the prospective analyses were further validated
using metabolomics data from 2007 (n 5 1,509 with
4-year follow-up). All three adulthood examinations
included assessment of anthropometrics and routine
cardiovascular risk factors, including levels of liver
enzymes and questionnaire-based data on alcohol con-
sumption and smoking status. All participants provid-
ed written informed consent, and the study was
approved by the local ethics committees. The study
protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki.
ASSESSMENT OF CLINICAL
CHARACTERISTICS
In the clinical examinations, waist circumference,
weight, and height were measured and body mass
index (BMI) was calculated as kilograms per square
meters. Blood pressure was measured with a random-
zero sphygmomanometer. Venous overnight fasting
blood was drawn for biomarker analyses. Data on ciga-
rette smoking (no versus yes), leisure-time physical
activity (an index score ranging 5-15),(14) mental disor-
ders, cancer, and alcohol consumption were collected
using questionnaires. To characterize long-term alco-
hol consumption, the mean value of standard drinks
per day assessed in 2001, 2007, and 2011 was used. A
categorized four-level alcohol intake variable was con-
structed as described.(15) Complete information on his-
tory of human immunodeﬁciency virus and hepatitis C
was obtained from the Finnish National Hospital Dis-
charge Register. None of the participants had a diag-
nosis of hepatitis C or human immunodeﬁciency virus,
which could potentially have contributed to the diag-
nosis of fatty liver.
METABOLITE QUANTIFICATION
A high-throughput NMR metabolomics platform
was used for the quantiﬁcation of 68 lipid and metabo-
lite measures that represent a broad molecular
signature of systemic metabolism from serum samples
collected in 2001, 2007, and 2011.(16-19) All metabo-
lites were measured using a single experimental setup
that allows for the simultaneous quantiﬁcation of rou-
tine lipids, lipoprotein subclass distributions, fatty
acids, as well as other low–molecular weight metabo-
lites, such as amino acids and glycolysis-related metab-
olites in absolute concentration units (e.g., millimoles
per liter). NMR-based metabolic proﬁling has been
employed in various epidemiological and genetic stud-
ies,(20-22) details of the experimentation have been
described, and the method has recently been
reviewed.(16,17) Concentrations of serum high-
sensitivity C-reactive protein and serum activity of
gamma-glutamyl transferase, aspartate aminotransfer-
ase, and alanine aminotransferase were measured using
standard clinical laboratory methods; and serum insu-
lin was measured by microparticle enzyme immunoas-
say.(13,23) These conventional biomarkers of fatty liver
were analyzed here to facilitate comparison with the
reported metabolic associations.
IMAGING OF THE LIVER FAT
STATUS
Ultrasonographic examinations were performed
with Acuson Sequoia 512 ultrasound mainframes
(Acuson, Mountain View, CA). The liver fat was
scanned using 4.0-MHz adult abdominal transducers.
All participants with images of acceptable quality were
included in the study. A trained sonographer graded
the liver fat status from the ultrasonographic images
using ﬁve widely accepted criteria for fatty liver: (1) the
liver-to-kidney contrast, (2) parenchymal brightness,
(3) deep beam attenuation, (4) bright vessel walls, and
(5) visibility of the neck of the gallbladder. For statisti-
cal analyses, we used a binary outcome variable (normal
liver versus fatty liver) based on the sonographer’s clini-
cal judgment of the image data. In addition, a categori-
cal fatty liver score (0-9) was formed based on the
above criteria, as detailed in Supporting Table S1.
STATISTICAL ANALYSIS
Variables with skewed distributions were log-
transformed prior to the analyses. Metabolic associa-
tions with the dichotomous fatty liver diagnosis were
assessed using logistic regression models separately for
each metabolic measure. Cross-sectional associations
were assessed with fatty liver status as outcome and the
metabolic measure from the same time point as the
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explanatory variable, with adjustment for age and sex.
The analyses were further assessed with additional
adjustment for waist circumference (or alternatively for
BMI), alcohol consumption, physical activity index,
and smoking status (fully adjusted model; mean substi-
tution was used for missing values [<3.1%]). Similar
logistic regression models were employed for the pro-
spective analyses, with metabolite levels and covariates
from the year 2001 or 2007 baseline data used as pre-
dictors of fatty liver status in 2011. To minimize the
number of individuals with a possible fatty liver at
baseline in 2001 or in 2007, participants having alanine
aminotransferase >30 U/L were excluded from these
analyses.(24,25) In order to facilitate comparison across
different metabolic measures, odd ratios (ORs) from
the logistic regression models were scaled to 1 standard
deviation (SD) increment in metabolite concentration.
All analyses were conducted without stratiﬁcation
because we found no interaction attributable to sex or
high versus low alcohol consumption (using 30 g/day
in men and 20 g/day in women as the cutoff point).
Continuous associations between the 68 metabolic
measures and the 0-9 categorical fatty liver score were
assessed by Spearman correlations. Multiple testing
correction was performed by accounting for 68 tests
using the Bonferroni method, with P < 0.0007 consid-
ered statistically signiﬁcant.
Results
The present study examined 2,002 participants aged
34-49 with the fatty liver assessment conducted by
ultrasound along with a comprehensive metabolic pro-
ﬁle quantiﬁed from a serum sample provided on the
same day in 2011. In addition, 1,575 of the study par-
ticipants had metabolic data based on serum samples
from 2001 available, which made it possible to assess
10-year prospective associations. The overall preva-
lence of fatty liver was 18.6% (n 5 372), with the prev-
alence being higher in men (28.0%) than in women
(10.8%). The clinical characteristics of the individuals
with and without fatty liver are summarized in Table
1. Mean concentrations (SD) of the 68 metabolic mea-
sures analyzed are listed for normal liver and fatty liver
participants in Supporting Table S1.
We have previously presented the cross-sectional
associations of conventional metabolic risk factors with
fatty liver in the Cardiovascular Risk in Young Finns
Study.(6) Here, we report the cross-sectional and pro-
spective associations for selected risk markers to facili-
tate interpretation of the association magnitudes
observed for the metabolic measures quantiﬁed by
NMR metabolomics. The strongest ORs for the pres-
ence of fatty liver were observed for waist, insulin,
TABLE 1. Clinical Characteristics of the Study Participants in 2011 and ORs for the Prevalence of Fatty Liver
Normal Liver
Status (n 5 1,630)
Fatty Liver
Status (n 5 372)
ORMean SD Mean SD 95% Confidence Interval
Men 40.1% — 68.3% — 3.32† 2.61-4.23
Age (years, range) 41.6 (34-49) 43.2 (34-49) 1.07‡ 1.05-1.10
Circulating biomarkers
Aspartate aminotransferase (U/L)* 21.6 10.4 31.8 32.3 1.98 1.74-2.25
Alanine aminotransferase (U/L)* 14.8 9.7 31.7 36.4 3.34 2.85-3.91
Gamma-glutamyl transferase (U/L)* 27.6 27.7 62.5 70.8 2.78 2.41-3.21
Insulin (mU/L)* 8.1 9.4 18.2 23.3 3.60 3.03-4.27
C-reactive protein (mg/L)* 1.70 2.70 3.15 4.17 2.20 1.92-2.51
Anthropometrics and blood pressure
Waist circumference (cm)* 88.7 12.2 105.4 14.2 3.80 3.22-4.49
BMI (kg/m2)* 25.5 4.3 30.9 5.6 3.34 2.88-3.89
Systolic blood pressure (mm Hg) 117 13 127 14 1.80 1.59-2.03
Diastolic blood pressure (mm Hg) 73 10 82 10 2.02 1.77-2.30
Behavioral variables
Leisure-time physical activity (5-15) 9.2 1.8 8.3 1.8 0.79 0.73-0.84
Smoking prevalence (%) 14.2 18.0 1.27 0.92-1.75
Alcohol intake (categorized 1-4) 1.85 0.58 2.11 0.73 1.54 1.27-1.87
Characteristics data are mean (SD). Age- and sex-adjusted odd ratios and their 95% conﬁdence intervals are per 1-SD increment in
circulating biomarkers, anthropometric variables and blood pressure, and per 1-step increment in sex, age, and behavioral variables.
*Log-transformed prior to calculating the ORs.
†Age-adjusted OR.
‡Sex-adjusted OR.
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alanine aminotransferase, and male sex (Table 1). For
instance, each 1-SD unit increment in waist circumfer-
ence (12 cm) was associated with a 3.8-fold higher risk
for prevalent fatty liver.
CROSS-SECTIONAL
ASSOCIATIONS OF METABOLITE
MEASURES WITH FATTY LIVER
The cross-sectional ORs for fatty liver for each meta-
bolic measure are shown in Fig. 1. Age-adjusted and
sex-adjusted associations are indicated by blue bars.
Overall, 60 out of 68 metabolic measures were robustly
associated with fatty liver in cross-sectional settings
(P < 0.0007). The ORs were attenuated upon addi-
tional adjustment for alcohol consumption, waist cir-
cumference, physical activity index, and smoking (red
bars); but 41 measures remained signiﬁcant at P <
0.0007. The corresponding metabolite associations
adjusted for BMI rather than waist circumference are
listed in Supporting Table S2. High concentrations of
large VLDL particles, and particularly the triglyceride
concentration in extremely large VLDL particles, were
most strongly reﬂective of the presence of fatty liver.
Higher concentrations of large high-density lipoprotein
(HDL) particles were robustly inversely associated with
fatty liver, whereas higher concentrations of small HDL
particles were directly associated with fatty liver. Several
measures of lipoprotein particle size were also strongly
associated with the presence of fatty liver, with inverse
associations observed for both low-density lipoprotein
and HDL particle diameters. Triglyceride-related lipid
measures were generally more strongly associated with
fatty liver than the corresponding cholesterol measures
within the same lipoprotein subfractions.
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FIG. 1. Cross-sectional associations of metabolic measures with presence of fatty liver (n 5 1,939-2,002 of whom 339-372 had diag-
nosed fatty liver in 2011). ORs and their 95% conﬁdence intervals are per 1 standard deviation increment in the metabolic measures
and shown with adjustment for sex and age (blue) and additionally for waist, alcohol intake, leisure-time physical activity and smoking
(red). P values listed in exponential format denote metabolite associations that were statistically signiﬁcant associations when account-
ing for Bonferroni correction (P < 0.0007). Abbreviations: Apo, apolipoprotein; CI, conﬁdence interval; DHA, docosahexaenoic acid;
FA, fatty acid; HOMA-IR, homeostatic model assessment of insulin resistance; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
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The proportions of speciﬁc fatty acids relative to the
total fatty acids were also strongly associated with fatty
liver. Polyunsaturated fatty acids were robustly inverse-
ly associated with fatty liver, in particular for n-6 (i.e.,
omega-6) fatty acids. The levels of both monounsatu-
rated and saturated fatty acids were directly associated
with fatty liver status, albeit not as strongly as observed
for serum triglycerides. Many small molecules in the
circulation were also robustly associated with fatty liver,
this being most prominent for elevated concentrations
of branched-chain and aromatic amino acids. Higher
levels of the inﬂammatory markers glycoprotein acetyls
and C-reactive protein were also associated with fatty
liver. The ORs for many of the metabolic measures
quantiﬁed by NMR metabolomics were of similar
magnitude or higher than those of conventional risk
markers of fatty liver (Table 1).
In addition to the analyses of the binary diagnosis of
fatty liver, we calculated Spearman’s correlation coefﬁ-
cients between the categorical fatty liver score and all
metabolic measures (Supporting Table S1). The corre-
lation pattern was highly consistent with the above-
mentioned association pattern of metabolites with the
dichotomous measure of fatty liver.
PROSPECTIVE ASSOCIATIONS OF
METABOLIC MEASURES WITH
FATTY LIVER
To examine how metabolic disturbances relate to
the risk of future onset of fatty liver, we tested the 10-
year predictive associations of the metabolites which
had been measured in 2001 (baseline; when the study
population was aged 24-39) with the fatty liver
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FIG. 2. Prospective associations of metabolic measures with 10-year risk for fatty liver (n 5 1,516-1,575 with metabolite data at the
2001 baseline, of whom 263-275 had fatty liver diagnosed in 2011). ORs (95% conﬁdence intervals) are per 1 standard deviation
increment in the baseline metabolic measures and shown with adjustment for sex and age (blue) and additionally for baseline waist,
alcohol intake, leisure-time physical activity, and smoking (red). P values listed in exponential format denote metabolite associations
that were statistically signiﬁcant associations when accounting for Bonferroni correction (P < 0.0007). Individuals with suspected fatty
liver in 2001 were excluded from analyses (alanine aminotransferase >30 U/L). Abbreviations: Apo, apolipoprotein; CI, conﬁdence
interval; DHA, docosahexaenoic acid; FA, fatty acid; HOMA-IR, homeostatic model assessment of insulin resistance; IDL,
intermediate-density lipoprotein; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty
acid; SFA, saturated fatty acid.
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diagnosed in 2011. Fifty-four individuals who showed
evidence of the presence of fatty liver disease were
excluded at the baseline in 2001 as their levels of ala-
nine aminotransferase were >30 U/L. The metabolic
associations with the 10-year risk for fatty liver are
shown in Fig. 2, with age-adjusted and sex-adjusted
associations again shown in blue. In general, the pro-
spective association pattern was very similar and only
modestly weaker than the corresponding cross-
sectional associations. Aberrations in lipoprotein
metabolism and fatty acid balance were predictive of
the 10-year risk for fatty liver even after adjusting for
baseline waist circumference (or alternatively for BMI,
Supporting Table S2), smoking, physical activity, and
alcohol intake. Disturbances in the circulating concen-
trations of amino acids and various glycolysis precur-
sors also preceded the onset of fatty liver. Interestingly,
the ORs for many of the metabolic biomarkers from
NMR proﬁling were as strong predictors of the 10-
year risk as observed for more established risk markers
such as levels of liver enzymes and insulin resistance
index.
We further validated the prospective biomarker
associations with fatty liver risk based on the metabo-
lite concentrations quantiﬁed from serum samples
drawn in 2007 (n 5 1,509). The ORs for the 4-year
risk of fatty liver are shown in Supporting Fig. S1.
These validation analyses demonstrated highly coher-
ent results between the metabolic association patterns
for 4-year and 10-year risks of fatty liver. Furthermore,
all results remained essentially unaltered if excluding
participants suffering from psychotic disorders or can-
cer in 2011 (12.5% of the study population) from the
analyses.
Discussion
In this large prospective study of fatty liver in
young and middle-aged adults, detailed metabolic
proﬁling revealed a myriad of circulating biomarkers
associated not only with the presence of fatty liver but
also with a future risk of developing this disease.
Prominent metabolic biomarkers for the risk of fatty
liver were observed among lipids and lipoprotein sub-
classes, fatty acid composition, and numerous low–
molecular weight metabolites, such as amino acids
and glycolysis-related metabolites. Many of the bio-
marker associations were comparable with or even
stronger than those of traditional risk markers of fatty
liver, such as BMI, liver enzymes, insulin resistance
index, and serum triglycerides and HDL cholesterol
(Table 1 and Fig. 1). The pattern of metabolic bio-
markers linked with fatty liver disease was observed
up to 10 years prior to the ultrasonographically
detected fatty liver, suggesting that the diverse altera-
tions in the systemic metabolism precede the onset of
fatty liver in apparently healthy young adults. The
prospective biomarker associations cover multiple
metabolic pathways and, perhaps surprisingly,
remained robust even when adjusted for routine risk
markers of fatty liver. These results reveal many novel
metabolic aberrations characterizing the presence of
fatty liver and provide insights into the metabolic
dynamics of the pathogenesis.
The overall metabolic signature of fatty liver
observed in the cross-sectional analysis was corre-
spondingly perturbed both 4 years and 10 years preced-
ing the clinically detected fatty liver. The detailed
association pattern of metabolic biomarkers linked
with the presence of fatty liver is reminiscent of the
metabolic deviations caused by higher adiposity.(23)
However, almost all of the biomarkers for fatty liver
disease remained predictive, albeit attenuated, when
adjusting for waist circumference and behavioral risk
factors. The strongest individual biomarkers not only
for the presence of fatty liver but also for its future risk
were VLDL particles and the related triglyceride con-
centrations. These results are in line with several
reviews summarizing the most important metabolic
biomarkers linked with prevalent fatty liver dis-
ease(1,7,26) but are here extended to long-term prospec-
tive analyses of the early manifestations of fatty liver in
young and middle-aged men and women. The ﬁnd-
ings regarding circulating triglycerides are not unex-
pected in view of the intrinsic role of hepatic
triglyceride accumulation in the pathogenesis of fatty
liver.(1) Recently, increase in the mean size of VLDL
particles and decrease in small VLDL particle concen-
tration have been linked to the severity of the more
advanced disease states, i.e., steatohepatitis and ﬁbro-
sis.(27) Nevertheless, the particularly strong associations
of the very largest VLDL particles and the prospective
nature of these results are novel observations. Similar
to the systemic perturbations resembling those
encountered in the metabolic syndrome, low large
HDL particle concentration and low HDL size dis-
played prominent associations as biomarkers for fatty
liver. In contrast, low-density lipoprotein particle con-
centrations were much weaker predictors of fatty liver
than the other lipoprotein measures. However, small
low-density lipoprotein particle size was strongly
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predictive of fatty liver, in agreement with previous
reports from cross-sectional settings in older individu-
als.(23,28) Overall, these ﬁndings indicate that early
metabolic aberrations in the lipoprotein subclass proﬁle
seem to precede the development of fatty liver.
The composition of serum fatty acids was strongly
predictive of the risk for fatty liver. For example, n-6
fatty acids, and to a weaker extent n-3 fatty acids, were
inversely associated with the prevalence of fatty liver.
These biomarker relations are similar to those observed
for incident type 2 diabetes(29) and cardiovascular dis-
ease.(20) Similarly, an increased monounsaturated fatty
acid proportion in the circulation has been associated
with a higher cardiovascular risk(20) and was here
robustly directly associated with the risk of fatty liver
disease. Coherent results on the fatty acid balance have
been observed in small cross-sectional studies compar-
ing nonalcoholic steatohepatitis patients to healthy
lean controls(10) and steatosis patients with type 2 dia-
betes.(30) The association patterns were similar in the
cross-sectional and prospective analyses, and the ORs
remained robust also for the 10-year risk of incident
fatty liver. This emphasizes the long-term predictive
value of these fatty acid ratios. Furthermore, the ORs
for the fatty acid measures were only modestly attenu-
ated after covariate adjustment, suggesting that these
biomarker associations may not be mediated simply by
adiposity and physical inactivity. Instead, the mecha-
nisms behind the links between fatty acids and liver fat
may relate to the interplay between fatty acids and
gene expression. For example, polyunsaturated fatty
acids may inﬂuence liver fat accumulation because
long-chain polyunsaturated fatty acids can affect sig-
naling molecules that inhibit lipogenesis and increase
beta-oxidation.(31) Our present ﬁndings are in accor-
dance with these putative mechanisms.
Notwithstanding the importance of lipid measures
in the metabolic syndrome and their potential role in
the pathogenesis of fatty liver, many biomarkers in
other metabolic pathways were also strongly linked
with the risk for fatty liver. Circulating levels of
branched-chain and aromatic amino acids were strong-
ly directly associated with the presence of fatty liver as
well as its future risk, conﬁrming previous small cross-
sectional studies.(32-34) Deviating levels of these amino
acids have been considered to be attributable to dys-
functional mitochondrial energy metabolism, adiposi-
ty, and insulin resistance and have been associated with
the risk for the development of type 2 diabetes in
multiple studies.(22,23,33,35-37) Prospective studies have
suggested that aberrations in the dispositions of
branched-chain and aromatic amino acids precede
insulin resistance,(35) and here we extend these ﬁndings
by revealing the predictive associations with the 10-
year risk for fatty liver. In addition, the levels of
glutamine have been inversely associated with insulin
resistance and diabetes risk,(35,38) and here the
glutamine concentration in serum was also inversely
associated with the presence of fatty liver. The pro-
spective associations of several glycolysis-related and
gluconeogenesis-related metabolites and glycoprotein
acetyls (a marker of low-grade inﬂammation)(39) were
also reﬂective of the presence of and the future risk for
fatty liver. These observations illustrate how multiple
pathways in the systemic metabolism are perturbed
prior to the development of fatty liver. The results pro-
vide a plethora of novel biological insights into the
pathogenesis of fatty liver in the general population.
Furthermore, the diverse metabolic perturbations
observed already in young and middle-aged adults with
fatty liver disease help to clarify the role of fatty liver as
a risk factor for cardiovascular disease(40,41): our results
demonstrate that a diagnosis of fatty liver is accompa-
nied by pronounced disturbances throughout the sys-
temic metabolic proﬁle. Using the same metabolomics
platform as applied here, we have recently shown that
elevated circulating levels of aromatic amino acids and
monounsaturated fatty acid proportions, as well as low-
er n-3 and n-6 fatty acid levels, are predictive of a
higher cardiovascular event risk on top of the well-
established risk factors.(18) These molecular perturba-
tions appear to arise before there is any clinically
detectable fatty liver and are therefore likely indepen-
dent of potential atherogenic effects caused directly by
hepatic steatosis. The biological mechanisms underly-
ing many of the observed biomarker associations
remain elusive. Further investigations will be required
to clarify the potential causal relations of these meta-
bolic markers in the pathogenesis of fatty liver.
This study has both strengths and limitations. Fatty
liver was diagnosed based on semiquantitative ultraso-
nography, which has limitations in terms of low sensi-
tivity.(42) The methodology was chosen for its
feasibility to be applied in large population studies. We
were unable to detect severe conditions beyond mild
steatosis; however, the relatively young age of the
asymptomatic population suggests that the prevalence
of severe steatosis would be minimal.(43) Coherent
associations with metabolic biomarkers were obtained
when analyzing fatty liver as a categorical score. The
lack of ultrasound-based fatty liver diagnosis at the
2001 survey (baseline for metabolic biomarkers)
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prevented formal analyses of fatty liver incidence; how-
ever, the young age group, long follow-up, and exclu-
sion of individuals with high baseline alanine
aminotransferase are all likely indicators of the minimal
prevalence of fatty liver at baseline. The lack of replica-
tion in an independent cohort is a limitation. However,
the concordant results of the prospective analyses at
two different time points enhance the validity of the
biomarker ﬁndings. The strengths of the study include
the large population-based setting of relatively young
participants with small loss to follow-up and consistent
ﬁndings from detailed metabolic proﬁling at three time
points during the 10 years of follow-up.
In conclusion, circulating biomarkers from multiple
metabolic pathways are strongly reﬂective of the pres-
ence of mild steatosis in asymptomatic young adults.
The metabolic biomarkers are also predictive of the
risk for fatty liver 10 years prior to its diagnosis, indi-
cating that many aberrations in the systemic metabolic
proﬁle seemingly precede the onset of overt fatty liver.
These results shed new light on the multiple metabolic
pathways related to fatty liver and may eventually make
it possible to achieve early detection of fatty liver dis-
ease and subsequently to target preventive strategies
based on the detailed metabolic proﬁle of an
individual.
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